A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients
- 13 September 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 106 (2), e153-e157
- https://doi.org/10.1097/tp.0000000000003953
Abstract
Background: Coronavirus-19 disease (COVID-19) has resulted in significant morbidity and mortality in solid organ transplant recipients. In December 2020, at the peak of the Los Angeles outbreak, our center rapidly implemented a protocol to improve outpatient management and provide Bamlanivimab or Casirivimab-Imdevimab (COVID mAb therapies) to all eligible COVID-19 positive liver and kidney transplant recipients. Methods: A retrospective review of all abdominal organ transplant recipients who were COVID-19 PCR+ between 2/2020-2/2021 from our center was performed. Patient demographics, COVID-19 treatments, hospitalizations, and survival were reviewed. Patients were considered eligible for COVID mAb therapy if they meet outpatient criteria at the time of diagnosis. Results: In the study period, 121 kidney transplant recipients (KG) and 105 liver or combined liver/kidney transplant recipients (LG) were COVID-19 PCR+. Hospitalization rates were similar for the KG (45%) versus LG (35%) (p=.20) but mortality was higher for the KG (22%) when compared to LG (10%) (p=.02). Our programmatic response, including outpatient COVID mAb therapies, reduced hospitalizations (p=.01) and deaths (p=.01). 94 KG and 87 LG patients were identified as potentially eligible for COVID mAb therapy and 17 KG and 17 LG patients were treated. COVID mAb therapies reduced hospitalization from 32% to 15% (p=.045) and eliminated mortality (13% vs 0%, p=.04). Conclusions: An aggressive approach including outpatient COVID mAb therapy in the COVID+ abdominal organ transplant recipients significantly decreased hospitalization and death. Early outpatient intervention for COVID-19 disease in transplant patients should be considered where possible.This publication has 12 references indexed in Scilit:
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19The New England Journal of Medicine, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19The New England Journal of Medicine, 2021
- Assessment of Racial/Ethnic Disparities in Hospitalization and Mortality in Patients With COVID-19 in New York CityJAMA Network Open, 2020
- Racial Disparities in Coronavirus Disease 2019 (COVID-19) Mortality Are Driven by Unequal Infection RisksClinical Infectious Diseases, 2020
- COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literatureTransplantation Reviews, 2020
- Mortality Rates in Transplant Recipients and Transplantation Candidates in a High-prevalence COVID-19 EnvironmentTransplantation, 2020
- United States County-level COVID-19 Death Rates and Case Fatality Rates Vary by Region and Urban StatusHealthcare, 2020
- COVID-19 in Liver Transplant Recipients: An Initial Experience From the US EpicenterGastroenterology, 2020
- Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United StatesHealth Affairs, 2020
- Covid-19 and Kidney TransplantationThe New England Journal of Medicine, 2020